Adagio Therapeutics Stock Forecast, Price & News

+1.38 (+3.07 %)
(As of 09/23/2021 01:04 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume3,708 shs
Average Volume713,334 shs
Market Capitalization$5.02 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADGI News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Adagio Therapeutics logo

About Adagio Therapeutics

Adagio Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Adagio Therapeutics Inc. is based in WALTHAM, Mass.


Adagio Therapeutics (NASDAQ:ADGI)  Shares Down 2.8%
Adagio Therapeutics (NASDAQ:ADGI) Shares Down 2.8%
September 22, 2021 |
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Up  After Earnings Beat
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Up After Earnings Beat
September 21, 2021 |
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Down to $51.46
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Down to $51.46
September 20, 2021 |
Adagio Therapeutics (NASDAQ:ADGI) Reaches New 52-Week High at $59.50
Adagio Therapeutics (NASDAQ:ADGI) Reaches New 52-Week High at $59.50
September 17, 2021 |
Adagio Therapeutics (NASDAQ:ADGI)  Shares Down 6.4%
Adagio Therapeutics (NASDAQ:ADGI) Shares Down 6.4%
September 16, 2021 |
Adagio Therapeutics, Inc. (ADGI)
Adagio Therapeutics, Inc. (ADGI)
September 15, 2021 |
Adagio Therapeutics (NASDAQ:ADGI) Shares Up 4.2%
Adagio Therapeutics (NASDAQ:ADGI) Shares Up 4.2%
September 14, 2021 |
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Up to $53.90
Adagio Therapeutics (NASDAQ:ADGI) Shares Gap Up to $53.90
September 13, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.28 out of 5 stars

Medical Sector

1134th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

168th out of 193 stocks

Analyst Opinion: 1.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adagio Therapeutics (NASDAQ:ADGI) Frequently Asked Questions

Is Adagio Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adagio Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adagio Therapeutics stock.
View analyst ratings for Adagio Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Adagio Therapeutics?

Wall Street analysts have given Adagio Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adagio Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adagio Therapeutics' next earnings date?

Adagio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, December 20th 2021.
View our earnings forecast for Adagio Therapeutics

How were Adagio Therapeutics' earnings last quarter?

Adagio Therapeutics Inc (NASDAQ:ADGI) issued its quarterly earnings data on Sunday, September, 19th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.62.
View Adagio Therapeutics' earnings history

What price target have analysts set for ADGI?

4 analysts have issued twelve-month price targets for Adagio Therapeutics' stock. Their forecasts range from $33.00 to $60.00. On average, they expect Adagio Therapeutics' stock price to reach $47.50 in the next year. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for Adagio Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Adagio Therapeutics IPO?

(ADGI) raised $301 million in an initial public offering on Friday, August 6th 2021. The company issued 17,700,000 shares at $16.00-$18.00 per share.

What is Adagio Therapeutics' stock symbol?

Adagio Therapeutics trades on the NASDAQ under the ticker symbol "ADGI."

When did Adagio Therapeutics' quiet period expire?

Adagio Therapeutics' quiet period expired on Wednesday, September 15th. Adagio Therapeutics had issued 18,200,000 shares in its initial public offering on August 6th. The total size of the offering was $309,400,000 based on an initial share price of $17.00. During Adagio Therapeutics' quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Adagio Therapeutics?

Shares of ADGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagio Therapeutics' stock price today?

One share of ADGI stock can currently be purchased for approximately $46.30.

How much money does Adagio Therapeutics make?

Adagio Therapeutics has a market capitalization of $5.02 billion.

How many employees does Adagio Therapeutics have?

Adagio Therapeutics employs 2,021 workers across the globe.

What is Adagio Therapeutics' official website?

The official website for Adagio Therapeutics is

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.